BR112018002404A2 - composição de combinação compreendendo composto de fgf-18 - Google Patents

composição de combinação compreendendo composto de fgf-18

Info

Publication number
BR112018002404A2
BR112018002404A2 BR112018002404A BR112018002404A BR112018002404A2 BR 112018002404 A2 BR112018002404 A2 BR 112018002404A2 BR 112018002404 A BR112018002404 A BR 112018002404A BR 112018002404 A BR112018002404 A BR 112018002404A BR 112018002404 A2 BR112018002404 A2 BR 112018002404A2
Authority
BR
Brazil
Prior art keywords
compound
fgf
combination composition
inhibitor
composition
Prior art date
Application number
BR112018002404A
Other languages
English (en)
Inventor
Gigout Anne
brenneis Christian
H Ladel Christoph
Guehring Hans
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR112018002404A2 publication Critical patent/BR112018002404A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

a presente invenção refere-se ao uso de um composto de fgf-18 em combinação com um ingrediente ativo adicional, selecionado do grupo de um inibidor de il-6, um inibidor do receptor de il-6, um inibidor de ngf ou um composto de toxina botulínica. dita composição pode ser usada para o tratamento de um distúrbio da cartilagem, tal como osteoartrite ou lesão de cartilagem.
BR112018002404A 2015-08-13 2016-08-11 composição de combinação compreendendo composto de fgf-18 BR112018002404A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15180859 2015-08-13
PCT/EP2016/069177 WO2017025611A1 (en) 2015-08-13 2016-08-11 Combination composition comprising fgf-18 compound

Publications (1)

Publication Number Publication Date
BR112018002404A2 true BR112018002404A2 (pt) 2018-09-18

Family

ID=53835964

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018002404A BR112018002404A2 (pt) 2015-08-13 2016-08-11 composição de combinação compreendendo composto de fgf-18

Country Status (13)

Country Link
US (1) US20180236032A1 (pt)
EP (1) EP3334450A1 (pt)
JP (1) JP7140677B2 (pt)
KR (1) KR20180035911A (pt)
CN (1) CN107921095A (pt)
AU (1) AU2016306626A1 (pt)
BR (1) BR112018002404A2 (pt)
CA (1) CA2994638A1 (pt)
IL (1) IL257492B (pt)
MX (1) MX2018001816A (pt)
RU (1) RU2745453C2 (pt)
WO (1) WO2017025611A1 (pt)
ZA (1) ZA201800974B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111132997A (zh) 2017-09-21 2020-05-08 默克专利有限公司 包含fgf-18部分的融合蛋白

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2327413A1 (en) * 2004-07-06 2011-06-01 ZymoGenetics, Inc. Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use
EP2054050B1 (en) * 2006-08-25 2012-08-08 Ares Trading S.A. Treatment of cartilage disorders with fgf-18
PT2054050E (pt) * 2006-08-25 2012-09-17 Ares Trading Sa Tratamento de patologias da cartilagem
MY153781A (en) * 2007-08-10 2015-03-13 Regeneron Pharma High affinity human antibodies to human nerve growth factor
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
US10149893B2 (en) * 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis

Also Published As

Publication number Publication date
RU2018108592A3 (pt) 2020-02-26
ZA201800974B (en) 2019-04-24
RU2018108592A (ru) 2019-09-13
WO2017025611A1 (en) 2017-02-16
MX2018001816A (es) 2018-05-16
CN107921095A (zh) 2018-04-17
JP2018528186A (ja) 2018-09-27
IL257492B (en) 2022-06-01
RU2745453C2 (ru) 2021-03-25
JP7140677B2 (ja) 2022-09-21
EP3334450A1 (en) 2018-06-20
CA2994638A1 (en) 2017-02-16
AU2016306626A1 (en) 2018-02-22
KR20180035911A (ko) 2018-04-06
US20180236032A1 (en) 2018-08-23
IL257492A (en) 2018-04-30

Similar Documents

Publication Publication Date Title
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
BR112018010585A2 (pt) composições de betume compreendendo lignina
BR112016003201A2 (pt) inibidores de grp94 seletivos e usos dos mesmos
BR112019006642A2 (pt) antagonistas multiméricos de e-selectina altamente potentes
MX2018007155A (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj).
BR112019016497A2 (pt) 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de câncer.
BR112018010381A2 (pt) composições para tratamento de cabelo, condicionadora de cabelo e para alteração da cor do cabelo, sistema para tratamento de cabelo, métodos para tratamento de cabelo e para alteração da cor do cabelo, e, kit de multicompartimentos.
CL2014002257A1 (es) Compuestos derivados de 6-alquinilo piridinas, como mimeticos smac; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o prevencion del cancer.
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
UY37018A (es) Inhibidores bicíclicos de pad4
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
BR112018008103A2 (pt) análogos de celastrol
EA201492011A1 (ru) Безводные фармацевтические составы для местного применения
BR112017025711A2 (pt) ?composições, processo para preparação de siloxanos modificados por poliéter e uso das composições inovadoras?
BR112016021648A2 (pt) novos compostos
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
BR112017008045A2 (pt) compostos como inibidores de nik
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
BR112018006545A2 (pt) ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
BR112018006314A2 (pt) composto da fórmula, composição, uso de composto da fórmula, método de combate a fungos fitopatogênicos e semente revestida
BR112017006515A2 (pt) moléculas biespecíficas, composições, método para tratar ou prevenir infecção por hiv-1 em um indivíduo com essa necessidade, e vetor
BR112015029354A2 (pt) Composição para prevenir ou tratar degradação de cartilagem, e uso de rutina
BR112016022749A2 (pt) compostos de azole substituído por amido como inibidores de tnks1 e/ou tnks2
BR112018010692A2 (pt) composições imunoestimuladoras, usos de melanina ou de um precursor da melanina e método para obter uma composição imunoestimuladora

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]